Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesTempest Therapeutics Inc

Tempest Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.397 USD 0.02 ( 6.09%)
Last update at 2026-11-11T21:25:00Z
VOLUME
1433089
Market Cap
12.49M

Momentum Score

…

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.38
Low
0.48
High
52 Week Price Range
0.74
Low
12.23
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.37
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
1.22
ROE
-931.14%
Net Debt
0.43M
ROCE
-191.34%
Diluted EPS TTM
-3.60

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -26.26M -41.84M -29.49M -35.71M -28.30M
Net income -26.26M -41.84M -29.49M -36.78M -29.55M
Selling general administrative 13.97M 13.55M 11.66M 12.11M 9.82M
Selling and marketing expenses - - 0.38M - -
Gross profit - -0.39M -0.38M -1.81M -1.27M
Reconciled depreciation 0.27M 0.39M 0.51M 0.64M 0.37M
Ebit -26.05M -40.53M -29.16M -34.64M -26.99M
Ebitda -25.79M -40.14M -28.78M -34.09M -26.65M
Depreciation and amortization 0.27M 0.39M 0.38M 0.55M 0.34M
Operating income -26.57M -42.03M -29.16M -34.64M -26.99M
Other operating expenses 26.57M 42.03M 29.16M 34.64M 26.99M
Interest expense 0.21M 1.32M 1.45M 1.62M 1.28M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.52M 1.50M 1.10M 0.55M 0.07M
Net interest income 0.31M 0.18M -1.50M -1.62M -1.28M
Income tax expense - -41.84M - 1.07M 1.25M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 26.57M 41.64M 28.78M 34.64M 26.99M
Cost of revenue - 0.39M 0.38M 1.81M 1.27M
Total other income expense net 0.31M 0.18M -0.33M -1.07M -1.32M
Net income from continuing ops -26.26M -41.84M -31.11M -35.71M -28.30M
Net income applicable to common shares - - - - -28.30M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 16.93M 41.49M 51.60M 46.09M 73.24M
Other current assets 0.56M 1.21M 1.13M 1.27M 0.55M
Total liab 10.26M 22.36M 24.84M 27.98M 37.12M
Total stockholder equity 6.67M 19.13M 26.77M 18.11M 36.12M
Other current liab 1.08M 4.55M 3.33M 4.76M 17.59M
Common stock 0.01M 0.04M 0.02M 0.01M 0.01M
Capital stock 0.01M 0.04M 0.02M 0.01M 0.01M
Retained earnings -233.37M -207.11M -165.26M -135.77M -100.06M
Other assets - - - - 0.11M
Cash 7.71M 30.27M 39.23M 31.23M 51.83M
Total current liabilities 3.31M 14.22M 9.41M 7.28M 20.03M
Net debt 0.43M -14.90M -18.57M -9.12M -33.29M
Short term debt 1.19M 7.22M 5.24M 1.41M 1.44M
Short long term debt - 6.35M 4.29M - -
Short long term debt total 8.14M 15.37M 20.66M 22.11M 18.54M
Other stockholder equity 240.03M 226.19M 192.01M 153.87M 136.17M
Property plant equipment - - - - 4.16M
Total current assets 8.27M 31.47M 40.36M 32.95M 68.96M
Net tangible assets - - - - 36.12M
Net receivables - - - 0.45M 15.00M
Long term debt - - 6.26M 10.37M 15.07M
Inventory - - - - 1.58M
Accounts payable 1.04M 2.45M 0.84M 1.11M 0.99M
Accumulated other comprehensive income - - 0.00M - -73.24M
Non currrent assets other 0.52M 0.10M 0.06M 0.43M 0.11M
Non current assets total 8.66M 10.01M 11.24M 13.14M 4.28M
Capital lease obligations 8.14M 9.01M 10.11M 11.74M 3.47M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.43M -0.52M -0.56M -0.10M
Change to liabilities - - - - -0.21M
Total cashflows from investing activities - -0.43M - - -0.10M
Net borrowings -6.43M -4.40M - - 15.00M
Total cash from financing activities 4.26M 24.50M 35.60M 11.40M 59.06M
Change to operating activities - - - - -0.40M
Net income -26.26M -41.84M -29.49M -35.71M -28.30M
Change in cash -22.56M -8.96M 8.00M -20.23M 33.01M
Begin period cash flow 30.71M 39.67M 31.23M 51.83M 18.82M
End period cash flow 8.15M 30.71M 39.23M 31.60M 51.83M
Total cash from operating activities -26.82M -33.03M -27.36M -31.07M -25.96M
Issuance of capital stock 7.33M 28.59M 1.27M 16.14M 33.42M
Depreciation 0.27M 0.39M 0.38M 0.64M 0.37M
Other cashflows from investing activities - - - - 0.04M
Other cashflows from financing activities 4.26M 0.31M 0.04M 7.28M 40.54M
Change to netincome - - - - 2.58M
Capital expenditures 0.00M 0.43M 0.17M 0.56M 0.14M
Change in working capital -5.13M 1.61M -2.68M 0.87M -0.61M
Stock based compensation 3.12M 5.30M 2.55M 1.56M 1.10M
Other non cash items 1.19M 1.51M 5.46M 1.57M 1.48M
Free cash flow -26.82M -33.46M -27.53M -31.63M -26.09M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
TPST
Tempest Therapeutics Inc		 0.02
6.09%		 0.40 - - - 22.94 0.31
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Tempest Therapeutics Inc

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

2000 Sierra Point Parkway, Brisbane, CA, United States, 94005

415 798 8589

https://www.tempesttx.com

4

Name Title Year Born
Mr. Stephen R. Brady J.D., LLM CEO & Director 1970
Dr. Thomas W. Dubensky Jr., Ph.D. Pres & Director 1958
Dr. Samuel Whiting M.D., Ph.D. Exec. VP & Chief Medical Officer NA
Mr. Nicholas Maestas VP of Strategy & Fin. and Sec. 1980
Mr. Justin Trojanowski Corp. Controller, Treasurer & Principal Accounting Officer 1988
Mr. Petpiboon Prasit Acting Chief Scientific Officer & Exec. Director NA
Dr. Sharon Sakai Ph.D., RAC Head of Regulatory & Quality NA
Dr. Anne Moon Sr. VP and Head of Project Team Leadership, Project Management & Portfolio Management NA
Mr. Stephen R. Brady J.D., LLM CEO, President & Director 1970
Dr. Samuel Whiting M.D., Ph.D. Executive VP & Chief Medical Officer 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…